These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
642 related articles for article (PubMed ID: 29253322)
21. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263 [TBL] [Abstract][Full Text] [Related]
22. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002 [TBL] [Abstract][Full Text] [Related]
24. Treatment for osteoporosis in people with beta-thalassaemia. Bhardwaj A; Swe KMM; Sinha NK Cochrane Database Syst Rev; 2023 May; 5(5):CD010429. PubMed ID: 37159055 [TBL] [Abstract][Full Text] [Related]
27. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Machado M; Cruz LS; Tannus G; Fonseca M Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097 [TBL] [Abstract][Full Text] [Related]
29. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA; Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037 [TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates for Patients Diagnosed With Multiple Myeloma. Mhaskar R; Djulbegovic B JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511 [TBL] [Abstract][Full Text] [Related]
31. Bisphosphonates and breast carcinoma. Lipton A Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434 [TBL] [Abstract][Full Text] [Related]
33. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641 [TBL] [Abstract][Full Text] [Related]
34. Treatment for osteoporosis in people with ß-thalassaemia. Bhardwaj A; Swe KM; Sinha NK; Osunkwo I Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506 [TBL] [Abstract][Full Text] [Related]
35. Interventions for managing medication-related osteonecrosis of the jaw. Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376 [TBL] [Abstract][Full Text] [Related]
36. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Wells GA; Hsieh SC; Zheng C; Peterson J; Tugwell P; Liu W Cochrane Database Syst Rev; 2022 May; 5(5):CD004523. PubMed ID: 35502787 [TBL] [Abstract][Full Text] [Related]
37. A systematic review of the role of bisphosphonates in metastatic disease. Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258 [TBL] [Abstract][Full Text] [Related]